Compare · IOVA vs XBIO
IOVA vs XBIO
Side-by-side comparison of Iovance Biotherapeutics Inc. (IOVA) and Xenetic Biosciences Inc. (XBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IOVA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while XBIO focuses on Biotechnology: Pharmaceutical Preparations.
- IOVA is the larger of the two at $3.38B, about 937.2x XBIO ($3.6M).
- IOVA has been more active in the news (14 items in the past 4 weeks vs 6 for XBIO).
- IOVA has more recent analyst coverage (21 ratings vs 0 for XBIO).
- Company
- Iovance Biotherapeutics Inc.
- Xenetic Biosciences Inc.
- Price
- -
- -
- Market cap
- $3.38B
- $3.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 14
- 6
- Recent ratings
- 21
- 0
Iovance Biotherapeutics Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Xenetic Biosciences Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Latest IOVA
- Interim CEO & General Counsel Vogt Frederick G exercised 200,000 shares at a strike of $7.55 and covered exercise/tax liability with 191,303 shares, increasing direct ownership by 1% to 604,144 units (SEC Form 4) to cover withholding tax
- Chief Commercial Officer Kirby Daniel Gordon converted options into 10,000 shares and covered exercise/tax liability with 3,935 shares, increasing direct ownership by 4% to 160,576 units (SEC Form 4) (withholding obligation)
- Iovance Biotherapeutics to Present at Upcoming Conference
- Chief Financial Officer Roche Corleen M. converted options into 12,500 shares and covered exercise/tax liability with 5,311 shares, increasing direct ownership by 25% to 35,946 units (SEC Form 4) (withholding obligation)
- SEC Form SCHEDULE 13G filed by Iovance Biotherapeutics Inc.
- Iovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by Iovance Biotherapeutics Inc.
- Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
- SEC Form 8-K filed by Iovance Biotherapeutics Inc.
Latest XBIO
- SEC Form DEFA14A filed by Xenetic Biosciences Inc.
- Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
- SEC Form 10-Q filed by Xenetic Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Xenetic Biosciences Inc.
- Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
- Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
- Xenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Xenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics